Skip to main content

Typhoid

4
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
6100%
+ 1 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
3 programs
3
Typhoid Vi vaccinePhase 4Vaccine1 trial
Typhoid Vi vaccinePhase 4Vaccine1 trial
Typhoid Vi vaccinePhase 4Vaccine1 trial
Active Trials
NCT00131820Completed100,742Est. Jan 2007
NCT00125008Completed37,673Est. Jan 2008
NCT00125047Completed27,231Est. Aug 2007
Emergent BioSolutions
1 program
1
Dose of 5.0 x 10^9 CFUPhase 21 trial
Active Trials
NCT00679172Completed187Est. Dec 2008
GSK
GSKLONDON, United Kingdom
3 programs
Typhoid Vi vaccinePHASE_4Vaccine
Typhoid Vi vaccinePHASE_4Vaccine
Typhoid Vi vaccinePHASE_4Vaccine

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ViiV HealthcareTyphoid Vi vaccine
ViiV HealthcareTyphoid Vi vaccine
ViiV HealthcareTyphoid Vi vaccine
Emergent BioSolutionsDose of 5.0 x 10^9 CFU

Clinical Trials (4)

Total enrollment: 165,833 patients across 4 trials

NCT00125008ViiV HealthcareTyphoid Vi vaccine

Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever

Start: May 2003Est. completion: Jan 200837,673 patients
Phase 4Completed
NCT00131820ViiV HealthcareTyphoid Vi vaccine

Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam

Start: Dec 2001Est. completion: Jan 2007100,742 patients
Phase 4Completed
NCT00125047ViiV HealthcareTyphoid Vi vaccine

Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood

Start: Oct 2001Est. completion: Aug 200727,231 patients
Phase 4Completed
NCT00679172Emergent BioSolutionsDose of 5.0 x 10^9 CFU

Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

Start: May 2008Est. completion: Dec 2008187 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

Vaccine is the dominant modality (100% of programs)
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.